About the
NeLM
|
Help & Support
|
Site Feedback
|
Update Newsletter Subscription
Homepage
Login
|
Register
Search the NeLM
Medicines A-Z
Find key information about medicines by name (prototype)
Browse by Categories:
BNF Category
|
Medical Specialty
|
National Health Service
|
Medicines Information
Browse by NeLM area:
Evidence
|
Other Library Updates
|
News
|
Health In Focus
|
Medicines A-Z
|
Communities
|
Useful Links
|
Formularies
National Health Service
Clinical governance / audit
Commissioning
Community pharmacy
CPD
General management
General practice
Government / regulatory
Health Economics
Healthcare statistics / epidemiology
Hospital trusts
Information provision
IT
Law/ medical ethics/ litigation
Medicines management
National Service Framework
NHS Direct / walk-in
Prescribing and supply of medicines
Primary Care Trusts
Professional bodies
Public Health
All Wales Medicines Strategy Group (AWMSG)
Audit Commission
Clinical Knowledge Summaries (CKS)
Commission for Healthcare Audit & Inspection (CHAI)
Department of Health (DH)
European Agency for the Evaluation of Medicinal Products (EMEA)
Food & Drug Administration (FDA)
Food Standards Agency (FSA)
Health Protection Agency
Health Service Circulars (HSCs)
Kings Fund
Medicines and Healthcare products Regulatory Agency (MHRA)
National Audit Office
National Institute of Clinical Excellence (NICE)
National Patient Safety Agency (NPSA)
National Treatment Agency
NHS Counterfraud Service
Pharmaceutical Services Negotiating Committee (PSNC)
Prodigy (formerly CKS)
Scottish Medicines Consortium
66 library items
in All Wales Medicines Strategy Group (AWMSG)
Filter results by:
Date Published
2012 (9)
2011 (26)
2010 (20)
2009 (11)
2008 (0)
NeLM
Area
News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies
Results filtered by:
Category
Government / regulatory (
remove
)
,
All Wales Medicines Strategy Group (AWMSG) (
remove
)
Sort by:
Least recent publication date
Most recent publication date
Title alphabetical A-Z
Title alphabetical Z-A
Source alphabetical A-Z
Source alphabetical Z-A
Display summary:
No
Yes
Results 1 - 10 of 66
Result page:
Previous
|
1
2
3
4
5
6
7
|
Next
1.
AWMSG issues Final Appraisal Recommendation on rosuvastatin (Crestor®)
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
19/01/2012
Category:
2.12 Lipid-regulating drugs
|
All Wales Medicines Strategy Group (AWMSG)
|
Drug reviews
|
Hyperlipidaemia
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link
2.
AWMSG issues Final Appraisal Recommendation on paliperidone palmitate (Xeplion®) prolonged release suspension for injection
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
19/01/2012
Category:
4.2.2 Antipsychotic depot injections
|
All Wales Medicines Strategy Group (AWMSG)
|
Drug reviews
|
Schizophrenia and disorders with psychotic features
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link
3.
AWMSG issues Final Appraisal Recommendation on dasatinib (Sprycel®)
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
19/01/2012
Category:
8.1.5 Other antineoplastic drugs
|
All Wales Medicines Strategy Group (AWMSG)
|
Drug reviews
|
Leukaemia
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link
4.
AWMSG Statement of Advice: Telavancin (Vibativ®) for the treatment of adults with nosocomial pneumonia
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
12/01/2012
Category:
5.1.7 Some other antibacterials
|
All Wales Medicines Strategy Group (AWMSG)
|
Bacterial
|
Infection control
|
Nasal problems
NeLM
Area:
News
Statement of Advice
5.
AWMSG Statement of Advice: Human normal immunoglobulin (Kiovig®) for immunomodulation in multifocal motor neuropathy
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
12/01/2012
Category:
14.5 Immunoglobulins
|
All Wales Medicines Strategy Group (AWMSG)
|
Neurology
NeLM
Area:
News
Statement of Advice
6.
AWMSG issues Final Appraisal Recommendation on the use of collagenase Clostridium histolyticum (Xiapex®▼) for the treatment of Dupuytren’s contracture
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
12/01/2012
Category:
10.3.1 Enzymes
|
All Wales Medicines Strategy Group (AWMSG)
|
Connective tissue disease
NeLM
Area:
Evidence
>
Drug Specific Reviews
Recommendation
7.
AWMSG issues Final Appraisal Recommendation on the use of alteplase (Actilyse® Cathflo® 2 mg) for unblocking occluded central venous access devices
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
12/01/2012
Category:
2.10.2 Fibrinolytic drugs
|
All Wales Medicines Strategy Group (AWMSG)
|
Drugs in renal failure
NeLM
Area:
Evidence
>
Drug Specific Reviews
Recommendation
8.
AWMSG issues Final Appraisal Recommendation on the use of saxagliptin (Onglyza®) for the treatment of type 2 diabetes mellitus
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
12/01/2012
Category:
6.1.2 Antidiabetic drugs
|
All Wales Medicines Strategy Group (AWMSG)
|
Diabetes
NeLM
Area:
Evidence
>
Drug Specific Reviews
Recommendation
9.
AWMSG issues Final Appraisal Recommendation on the use of tapentadol prolonged release (Palexia® SR) for the treatment of severe chronic pain
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
12/01/2012
Category:
4.7.2 Opioid analgesics
|
All Wales Medicines Strategy Group (AWMSG)
|
Pain control
NeLM
Area:
Evidence
>
Drug Specific Reviews
Recommendation
10.
AWMSG issues Final Appraisal Recommendation on the use of histamine dihydrochloride (Ceplene®) for acute myeloid leukaemia
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
03/11/2011
Category:
8.2.4 Other immunomodulating drugs
|
All Wales Medicines Strategy Group (AWMSG)
|
Leukaemia
NeLM
Area:
Evidence
>
Drug Specific Reviews
Recommendation
Results 1 - 10 of 66
Result page:
Previous
|
1
2
3
4
5
6
7
|
Next